Lue koko yhtiöanalyysi
Transcription
Lue koko yhtiöanalyysi
Company analysis FIT Biotech IPO Research 2.6.2015 Contents FIT Biotech 3 3 Investment highlights Company 4-10 Market 4 Product 5 Business model 6 Current portfolio development phase 7 Financials and shareholders 8 Management 9 Risks 10 Valuation 11-16 Summary of application valuations 11 One-off income and costs 12 Comparables 13 Recent deals in therapy development 14 HIV and Tuberculosis 15 Gene therapy and animal vaccines 16 HPV 17 Disclaimer 18 Contact Information 19 2 FIT Biotech Investment highlights Market for biopharmaceuticals is growing rapidly. Gene therapy solutions could potentially replace existing treatments such as therapeutic antibodies currently selling for over $60 billion and growing over 10% annually. New therapies involve inserting modified genes into human body to induce desired therapeutic molecules inside cells. FIT Biotech has a proprietary patented technology GTU (Gene Transport Unit) for transporting desired genes into human cells. GTU is considered a superior vector in comparison to currently used viral-vectors in terms of safety and to conventional DNA plasmid in terms of efficacy. The technology has been proven safe by FDA and EMA as demonstrated in previous studies by FIT Biotech related to HIV. GTU technology inducing the desired treatment GTU technology can be applied in a vast number of treatments and it can have several application areas of significant market potential. If found to be successful the potential market for GTU based drugs can reach up to $90 billion. FIT Biotech business model is based on early partnering with codevelopers to minimize the capital need and lower the development risks. FIT Biotech is a early stage biotechnology company with no current revenue and no binding partnership contracts with big pharmaceuticals. The cash flow is negative and possible future refinancing need cannot be excluded. The GTU technology can have correlation risks e.g. if the technology fails in one application it could lower the interest in the technology in other applications. • Modified genes • Modified genes inserted into the GTU vector • GTU vector carrying modified genes • GTU vector penetrates the cell membrane of the target cell • GTU vector transfers new gene inside the cell and its nucleus • Cell produces protein copying inserted genes • Desired molecule treatment begins FIT Biotech is a high risk high reward opportunity in fast developing biopharmaceuticals segment. The company GTU technology offers advantages to current vector solutions. The business model is based on partnering to lower the capital need of research and development offering a possibility for positive cash flows in accelerated phase. FIM Research Aaron Kaartinen (09) 6134 6430, aaron.kaartinen@fim.com Kim Gorschelnik (09) 6134 6422, kim.gorschelnik@fim.com Source: Company, FIM 3 Company Market Biopharmaceuticals Biological pharmaceuticals market Biopharmaceutical is a medical product that is manufactured or extracted from biological sources. This is distinct from traditional pharmaceutical products that are chemically synthesized. Major classes of biopharmaceuticals are recombinant antibodies, vaccines and still developing field of gene therapy. The benefit of biological pharmaceuticals is a more targeted treatment that enables a safer and more effective therapy than traditional chemical pharmaceuticals. The total market of biological pharmaceuticals is over 200 billion euros. The annual growth rate of biological pharmaceuticals is estimated to be over 10% and over twice the growth rate of the traditional chemical pharmaceuticals market. FIT Biotech’s GTU technology is a solution for transporting genes into human body and it can be utilized as a part of a biopharmaceutical vaccines and gene therapy. GTU provides the transportation method for the treatment gene. Therefore, the relevant market for FIT Biotech is exceptionally large as the GTU technology has potential to be applied as gene transportation method in many possible applications of biopharmaceuticals. Therapeutic antibodies Therapeutic antibodies are used in immunotherapy where the antibodies are used to bind target cells which may stimulate the patient’s immune system to attack those cells. Therapeutic antibodies is one of the largest segments of biological pharmaceuticals. DNA vaccines DNA vaccination is based on injecting genetically engineered DNA to produce an immune response to protect the organism. Currently the market is at very early stage with only few products in the market for human or animal use. Therefore, the expected average growth rate for the human DNA vaccines is over 50%. Source: Company, FIM 4 Company Product Gene Transfer Unit (GTU) a new generation non-viral gene delivery technology FIT Biotech was founded in 1995 and it has been focused on HIV vaccines. The HIV vaccine has reached phase II/a in 2009. During the research process in 2001 the company discovered a new proprietary technology for gene transport (“vector”) and has shifted its strategy to seek opportunities in licensing the vector. The Gene Transfer Unit (GTU) technology is based on E2-protein and is considered to be a new generation nonviral vector for delivery of DNA into cells. GTU technology can be a vector solution for gene therapy and a number of vectored vaccines. The technology has been patented in 2003 and the patents are valid through 2023 – 2024. Methods of antibody treatment are traditional antibodies and future gene therapy. Traditional antibodies are manufactured outside the human body. Antibodies are then injected intravenously resulting in high but quickly decreasing concentration of antibodies in blood. Gene therapy is based on producing the antibody inside the human body. This results in more stable and longer lasting therapeutic concentration of antibodies. Competing methods of transporting the genes are conventional DNA and viral vectors. Conventional DNA consists of plain DNA plasmid. The transportation method is safe but it has been found to be ineffective due to low transfection capacity and therefore nonfunctional transport mechanism. Viral vector as part of gene therapy is effective but is considered an unsafe method of transportation. GTU technology is considered safe by FDA and EMA. Furthermore, it is considered to be also effective as part of gene therapy solution. See the attached table for comparison between gene transportation technologies. Source: Company, FIM Gene transportation technologies Attribute GTU Viral vectors Conventional DNA Safety Excellent Satisfactory Excellent Transfection Good Excellent Poor Transient efficacy Excellent Excellent Poor Controlled efficacy Excellent Satisfactory Poor Utility in vaccines Mediocre Mediocre Satisfactory Utility in gene therapy Excellent Excellent Poor Manufacturing complexity Good Mediocre Good Manufacturing cost Good Mediocre Good 5 Company Business model Biotech companies earnings model in general In comparison to big pharmaceutical companies biotechnology companies are focused on researching and developing pharmaceuticals. Typically, biotech companies develop the pharmaceuticals to commercialization phase and license to / or become acquired by a “big pharma” company. The focus on the early phases of development results in high development risks and many biotech companies fail to reach the market at all. The risk profile is significantly different from established big pharmaceutical companies which focus on financing development projects and marketing the pharmaceuticals in the end market. FIT Biotech position in pharmaceutical value chain FIT Biotech focus Scientific research Pre-clinical Partner focus Phase 1 Phase 2 Phase 3 End market FIT Biotech’s business model is based on licensing GTU FIT Biotech’s business model is based developing the drug candidates through preclinical phase or up to clinical phase 1-2 and on finding a partner to co-develop the drug candidates in early stage to minimize the need of capital. This is based on the previously tested GTU technology, which can be applied in various applications. However, this business model is highly dependent on finding partners with financial capability for clinical trials at all three phases. Lower capital requirement Higher development risk Higher capital requirement Lower development risk Revenues consist of signing fees, milestone payments and royalty payments. The company receives signing fees after signing of a licensing contract. Milestone payments are received after certain milestones e.g. proof of clinical efficacy. Royalty payment starts after commercialization of the drug using GTU technology. Revenues are difficult to estimate. Possible revenues during next 5 years depend on negotiations with possible licensing partners and progress in the development stages for each drug application. FIT Biotech is a long-term case where the focus in the coming years is on possible news on important events. The value of the company increases in steps after progress in licensing negotiations and advances in development stages. Source: Company, FIM 6 Company Current portfolio development phase Application Description Development phase Discovery Pre-clinical Phase I Phase IIa X X Phase IIb Current phase Phase III At market HIV HIV immunotherapy X X Tuberculosis Therapeutic tuberculosis vaccine X Partially completed Preclinical studies required. Memorandum of understanding signed with Minhai Biotechnology in 2014 Animal Vaccines Therapeutic and preventive animal vaccines X Partially completed Preclinical studies required. Heads of Agreement signed with QYH Biological Corporation (2015) Gene Therapy Antibody therapy via gene therapy X Partially completed Preclinical studies on-going with Icosagen Genetic Adjuvant Substances to boost vaccine efficiency X Partially completed Preclinical studies required HPV Therapeutic HPV vaccine X Partially completed Preclinical studies required Ebola Therapeutic Ebola vaccine X Partially completed Preclinical studies required Source: Company, FIM Originally developed as a therapeutic vaccine. Phase II results published in 2010. Repositioned as immunotherapy and requires new phase II trials. Member of consortium to apply EU Horizon 2020 research program grant. 7 Company Financials and shareholders Financials FIT Biotech financials are typical to development phase biotechnology company with very limited revenue and negative retained earnings related to incurred costs of research and development. Convertible loans to be converted to equity during the IPO mostly at subscription price (conditional to the IPO). Capital loans from Tekes have been partially forgiven in 2015 (amounting to €11,8 million in IPO). Shareholders FIT Biotech shareholders include anchor investors including Sitra (Finnish State development fund), several large Finnish mutual pension funds and Inveni Secondaries (life science VC fund). Furthermore, as a result of earlier private placement the company has more than 200 private investors. Total number of pre-IPO investors amount to over 250. Shareholder structure Financials P&L Revenue Other operating income 2010 0,0 0,9 2011 0,0 0,8 2012 0,0 2,2 2013 0,1 0,5 2014 0,0 0,0 Materials Services Personnel costs Other costs EBITDA 0,0 0,0 -0,4 -0,6 -0,1 0,0 0,0 -0,4 -0,6 -0,1 0,0 0,0 -0,6 -1,1 0,4 0,0 -0,1 -0,6 -0,7 -0,7 0,0 0,0 -0,5 -0,6 -1,1 Depreciation & Amortization EBIT -1,2 -1,3 -2,4 -2,5 -2,5 -2,1 -1,8 -2,6 -0,8 -2,0 Net interest expenses Taxes -0,1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 Net profit -1,2 -2,5 -2,2 -2,6 -2,0 2010 4,1 0,0 0,1 4,2 2011 4,3 0,0 0,1 4,4 2012 2,9 0,0 0,0 2,9 2013 1,7 0,0 0,0 1,7 2014 1,2 0,0 0,0 1,2 Receivables Cash and cash equivalents Current assets 0,2 1,3 1,5 0,3 1,2 1,4 0,3 0,3 0,6 0,1 0,1 0,2 0,1 0,2 0,3 Total assets 5,7 5,8 3,5 1,9 1,5 2,1 2,2 -24,8 -1,2 -21,7 10,7 2,2 -26,1 -2,5 -15,6 12,9 0,0 -28,5 -2,2 -17,7 12,9 0,0 -30,7 -2,6 -20,3 14,2 0,0 -33,3 -2,0 -21,0 8,5 15,4 2,6 0,9 27,4 0,8 15,4 4,2 0,9 21,4 0,8 16,4 3,3 0,8 21,3 3,6 18,3 0,0 0,3 22,2 3,6 18,3 0,4 0,2 22,5 5,7 5,8 3,5 1,9 1,5 Balance sheet Intangible assets Tangible assets Investments Fixed assets Share Capital Other equity Retained earnings Net profit Equity Convertible loans Capital loans Loans from financial institutions Current liabilities Liabilities Source: Company, FIM Total equity & liabilities 8 Company Management Management team Board of directors Dr. Kalevi Reijonen, CEO Rabbe Slätis, Chairman of the Board Over 30 years of international experience in pharma and biotech industry (e.g. Spectrum Medical Sciences, Farmos and Orion). M.Sc. (Chemistry), has served as CEO of Novartis Participations AB and Sandoz Oy . Several Chairman of the Board, Managing Director and Director of Marketing and Sales positions during the last 25 years. Prof. Mart Ustav, Chief Scientific Officer Tina Nyfors, Board member Developing an HIV vaccine in FIT Biotech since 2000. International experience from US and Sweden as a molecular biologist. M.Sc., MBA, CIR, CEO and owner of Locnet Oy. Multiple Board memberships both in Finland and internationally. Corporate Secretary of ADB Holdings, plc, Switzerland. 20 years experience in corporate finance and executive management positions in private and public listed companies. Liisa Laitinen, VP Finance & Admin. Over 30 years experience in international business in Finland and abroad (e.g. Paloheimo, Dresdner Bank, Bank of America). Erkki Pekkarinen, Board member Jani Koskinen, VP Production MBA, has worked in BioFund Management since December 1999. Various positions in investment activities and financial administration. VP of production of FIT Biotech since 2005. 10 years of experience in process development and biological production. Jussi Seitsonen, VP Quality Assurance QA and QC manager of FIT Biotech since 2000. Juha Vapaavuori, Board member MSc., currently serves as Leading Expert in Life Sciences Team at the Finnish National Fund for Research and Development (Sitra). With a background in organic chemistry, previously Project Manager in Orion Corporation Fermion. Dirk Teuwen, Board member VP, Societal Corporate Responsibility and Senior Safety Advisor at UCB, Belgium. Scientific advisory board Dr. Richard A. Koup, Chief, Immunology Laboratory Vaccine Research Center, NIH (USA). Prof. Giuseppe Pantaleo, Professor of Medicine and Chief of the Laboratory of AIDS Immunopathogenesis at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne (Switzerland). Dr. Roger Le Grand, Head of the Department of Immuno-Virology of the Institute of Emerging Diseases and Innovative Therapies at CEA (France). Prof. A. Stanley Plotkin, Emeritus Professor of the University of Pennsylvania (USA) and Executive Advisor to Sanofi Pasteur (France). Prof. Michael M. Lederman, Professor of Medicine at Case Western Reserve University (USA). Source: Company, FIM 9 Company Risks General risks Biotechnology companies in general have very high risk profile in comparison to that of a typical listed company. Generally these companies have limited revenues and negative cash flows requiring additional financing rounds. FIT Biotech is an early stage development company and there is a significant risk that the company is unable to develop a product that reaches commercialization. All the applications are in early development stage. The most advanced R&D process is related to HIV (phase II/a). Illustrative example of development probabilities from FDA data is presented in the graph on the right. Approximately 8% of new drug applications reach the market. Furthermore, the company currently has a negative cash flow and it is possible that the company is unable to raise funds in the future, if needed. Indicative probabilties of reaching market 100 new drug applications 40 to phase I 30 to phase II 14 to phase III Company specific risks There is a risk that FIT Biotech will not be able to achieve collaboration agreements with potential partners. These collaborative agreements are critical to develop. Without these agreements the development of the application will stop. At this point FIT Biotech has preliminary agreements with a couple of companies. However there are no big pharma agreements regarding GTU technology at the moment. These kind of agreements and partners will be most likely needed to finalize the most expensive phases of the R&D process and the commercialization of applications to the end market. 9 to approval 8 to market FIT Biotech’s business case is very dependent on the GTU technology. This leads to correlation risk at least in some extent, in our opinion. Failure in pipeline for one application could lower the interest of the technology in other applications. Estimates of future cash flows is very complex and requires many assumptions critical to the value. Also the assumptions contain lots of uncertainties. Therefore, the resulting valuation is subject to high risk and should be considered as indicative. Source: Company, FIM 10 Valuation Summary of application valuations Valuation principles Risk adjusted valuation of applications The valuation is based on risk-adjusted discounted cash flow for each of the GTU application areas. Furthermore, cash flows from one-off income and costs are discounted separately. A separate market potential benchmarking is used to compare the valuation with listed Nordic peer companies (page 13) and recent deals in therapy development has been listed (page 14). Application The valuation is based on estimating the market size of the potential application. Current market size is expected to grow at initial market growth rate that is declining to a long term market growth of 1,5%. HIV Tuberculosis Gene therapy Anim al vaccines HPV 17,5 7,0 61,0 5,2 1,7 Initial market grow th 1,5 % 3,5 % 12,0 % 8,0 % 3,0 % Initial market share 1,0 % 1,0 % 1,0 % 2,0 % 9,0 % Market penetration rate 3,5 % 1,0 % 1,0 % 2,0 % 5,0 % Top market share 14,0 % 5,0 % 5,0 % 6,0 % 15,0 % Market size (EUR billion) Based on information received from the management we have estimated the commercialization date, the top market share of each application and the rate of yearly market penetration. Royalty-% 7,0 % 6,0 % 7,0 % 6,0 % 6,0 % Propability of approval 27,6 % 8,3 % 8,3 % 8,3 % 8,3 % The estimated royalty rate is then applied to the revenue stream of the applications market share to derive the income for FIT Biotech. The patent expiration date is set to be 10 years and the market share is expected to decline to zero in the subsequent 10 years. Joint propability The revenue stream is then discounted at 25% rate reflecting the high risks associated with the revenue estimate. The net present value is then adjusted to reflect the probability of entering into licensing arrangement and passing the required phases to enter the markets. Licensing arrangement probability is based on management estimates and the probability of passing different drug phases is based on FDA data on historical attrition rates. 70 % 70 % 70 % 80 % 70 % 19,3 % 5,8 % 5,8 % 6,6 % 5,8 % Commercialization year 2020 2019 2019 2019 2023 End of patent 2030 2029 2029 2029 2033 Discount rate 25 % 25 % 25 % 25 % 25 % DCF value 156 28 446 38 12 Propability adjusted DCF value 30 2 26 3 1 Propability of licensing Valuation summary of application valuations and post-IPO market cap Summary of valuation results The risk adjusted valuation for the application portfolio is in the range of €42-86 million. Net estimated one-off income (signing & milestone fees) and operating costs are (€5) million. Resulting enterprise value range is €37-81 million. Post-IPO net debt with €5 million cash subscription equals approximately €6 million including capital loans (TEKES) of €11,8 million and cash of €5,7 (excluding IPO costs). Resulting post-IPO market cap range is €31-75 million and €1,40-3,44 per share (€1,293,17 fully diluted). See graph on beside. Valuation details are presented in the following pages. NB. Estimates of future cash flows is very complex and requires many assumptions critical to the value. Also the assumptions contain lots of uncertainties. Therefore, the resulting valuation is subject to high risk and should be considered as indicative Source: Company, FIM 11 Valuation One-off income and costs One-off income We have separately estimated the one-off income related to the commercialization of GTU applications. The income estimate is based on the fees paid by the development partner. We expect the fees to include a signing fee and a milestone fee related to the final approval and commercialization of the developed drug. Our conservative estimate does not include intermediary fees as most of the phase I-III research and development would be done by the development partner. We have estimated the signing fee to be €5 million per application and commercialization milestone fee to be €10 million per application. These fee estimates are adjusted to reflect the probability of licensing (signing fee) and the probability of passing the development phases (milestone fees). Operating costs Discounted one-off income and costs 2015 2016 2017 2018 2019 0,0 0,0 3,5 HIV Tuberculosis 3,5 Gene therapy 3,5 Animal vaccines 4,0 3,5 HPV Total signing income 0,0 11,0 3,5 3,5 0,0 Milestone income Operating costs are expected to consist of marketing efforts and limited research and development. Long term cost inflation is expected to be 1,5%. HIV Tuberculosis 0,6 Discounted one-off income and costs Gene therapy 0,6 One-off income and operating costs are discounted using 25% discount rate and the net present value of the cash flow is (€5) million. Animal vaccines 0,7 1,9 0,7 HPV Total milestone income 0,0 0,0 0,0 0,0 1,8 2,6 0,0 Total one-off incom e 0,0 11,0 3,5 0,0 1,8 6,1 0,0 Total costs 2,0 2,5 4,0 5,0 5,0 5,0 5,0 -2,0 8,5 -0,5 -5,0 -3,2 1,1 -5,0 5,4 -0,3 -2,0 -1,0 0,3 -5,7 One-off income and costs Discount rate Discounted cash flow 25 % -1,6 Value of one-off incom e and costs Source: Company, FIM 2020 Terminal Signing income -4,9 12 Valuation Comparables Comparable valuation based on market potential Valuing early stage biotechnology companies with relative valuation (market or transaction multiples) is very challenging as these companies commonly have limited revenues, negative profitability and low or negative book value of equity. In order to perform an indicative relative valuation we have compared FIT Biotech market potential to similar early stage medical companies in the Nordic region. The market potential is based on estimates derived from comparable company prospectus, industry players or FIT Biotech management. The market potential is adjusted based on the phase of the application (i.e. probability adjustment). The enterprise value (EV) is divided by sum of probability weighted applications of the comparable company. The lower and upper quartile range of the multiple is very wide 4,8x – 29,6x and the FIT Biotech multiple of 3,3x – 7,3x falls in the lower range. Although the method does not take into account the market share potential of each application it gives some guidance on the relative value of the GTU innovation. Comparable valuation Company Herantis Nexstim Eurocine Bionor Pharma Biotie Therapies Cantargia Propability w eighted potential Application Eyedrops Phase I 2,2 20,7 % Parkinson Pre-clinical 3,2 8,3 % Secondary lymphedema Pre-clinical 0,5 8,3 % Stroke rehabilitation Phase III 1,6 57,6 % Mapping of the motor cortex Launched 0,1 100,0 % Influenza Phase III 5,7 57,6 % Pneumoccoccal Pre-clinical 4,0 8,3 % HIV Phase II 17,5 27,6 % Influenza Pre-Clinical 5,7 8,3 % Alcohol dependence Launched 1,0 100,0 % Parkinson Phase III 3,2 57,6 % Parkinson Phase II 3,2 27,6 % Inflammation Phase I n.a. 20,7 % Cancer Pre-clinical 70,0 8,3 % Sum of Enterprise EV / propability value (EUR Market w eighted million) potential applications 0,8 25 33,2 x 1,0 50 48,1 x 3,6 4 1,1 x 5,3 55 10,4 x 3,7 70 18,9 x 5,8 17 2,9 x Upper quartile 29,6 x Median 14,6 x Low er quartile 4,8 x FIT Biotech Source: Company, Comparable companies prospectus, Lundbeck, FIM Market potential (EUR billion) Development phase HIV Phase II 17,5 27,6 % Tuberculosis Pre-clinical 7,0 8,3 % Animal vaccines Pre-clinical 5,2 8,3 % Gene therapy Pre-clinical 61,0 8,3 % HPV Pre-clinical 1,7 8,3 % 11,1 37 - 81 3,3 x 7,3 x 13 Valuation Recent deals in therapy development Date Signing fees ($m) Milestone fees ($m) Total deal value ($m) Comments Adeno Associated Virus Vector 20 232 252 + royalties Royalties are not disclosed but are included in the deal Preclinical Adeno Associated Virus Vector 20 260 280 + royalties Royalties are double tier CNS diseases Preclinical / phase I Adeno Associated Virus Vector 65 745 810 + royalties Royalties are not disclosed but are included in the deal BristolMyers Squibb Cardiovascular diseases Preclinical / phase I Adeno Associated Virus Vector 95 471 566 + royalties Royalties are single to double-digit Janssen (Johnson & Johnson) Hephatitis B Phase I Electroporation n/a n/a 85 + royalties Royalties are not disclosed but are included in the deal Licensor Licensee Dimension Therapeutics Bayer 12/2014 Spark Therapeutics 02/2015 Target disease Phase Vector Hemophilia A Preclinical Pfizer Hemophilia B Voyager Therapeutics Genzyme (Sanofi) 04/2015 uniQure 04/2015 Ichor Medical Systems 07/2014 Recent deals in therapy development There has been several licensing deals with large pharmaceutical companies in gene therapy related therapies. The table above highlights some of the most relevant recent deals and the key components. In addition to licensing deals we highlight that a privately held US company REGENXBIO has received significant financing during 2015. REGENXBIO raised $30 million equity financing in January and 70,5 million mezzanine financing in May. REGENXBIO has developed a proprietary technology (NAV) based on adeno-associated viral (AAV) vector. REGENXBIO is mostly licensing the NAV technology to partners and we see its business model and vector technology focus to be similar to FIT Biotech. Source: Company, public news sources 14 Valuation HIV and Tuberculosis Key assumptions behind the estimates - HIV Key assumptions behind the estimates – Tuberculosis The market size for HIV pharmaceuticals is estimated to be 17,5 billion euros. The market is relatively mature and the growth rate is estimated to be 1,5%. The market share is expected to be relatively high 14% due to the significantly lower cost of the application in relation to current treatments. Royalty rate of 7% reflects the advanced phase II/a development phase. Probability of licensing is 70%. Commercialization date is expected to be 2020. The applied discount rate is 25%. The market size for tuberculosis vaccines is estimated to be 7,0 billion euros. The market growth rate is estimated to be 3,5%. The market share is expected to be relatively low 5% as the vaccine is a treatment vs. current preventive vaccines. Royalty rate of 6% reflects the lower potential mostly in developing counties such as China. Probability of licensing is 70%. Commercialization date is expected to be 2019. The applied discount rate is 25%. Discounted royalty and market share - HIV Discounted royalty and market share - Tuberculosis Sensitivity analysis - HIV Sensitivity analysis - Tuberculosis 2019 2020 2021 2023 21 % 62,1 52,1 43,7 36,6 25,8 23 % 53,0 43,8 36,1 29,8 20,3 25 % 45,6 37,0 30,0 24,4 16,1 27 % 39,4 31,5 25,1 20,1 12,8 29 % 34,2 26,9 21,2 16,7 10,3 Source: Company, FIM Top market share MEUR Year of commercialization MEUR 30,0 10 % 12 % 14 % 16 % 18 % 1,6 2017 2018 2019 2020 2022 -0,5 % 19,7 22,4 24,5 26,5 28,1 21 % 3,2 2,7 2,3 1,9 1,4 0,5 % 21,8 24,7 27,1 29,3 31,2 23 % 2,7 2,3 1,9 1,6 1,1 1,5 % 24,0 27,3 30,0 32,5 34,7 25 % 2,4 2,0 1,6 1,3 0,9 2,5 % 25,4 28,9 31,9 34,5 36,8 27 % 2,1 1,7 1,4 1,1 0,7 3,5 % 27,0 30,7 33,8 36,6 39,1 29 % 1,9 1,5 1,2 0,9 0,6 Initial market growth MEUR 2018 Discount rate Year of commercialization 30,0 Initial market growth Discount rate MEUR Top market share 1,6 1% 3% 5% 7% 9% 1,5 % 0,4 1,1 1,4 1,7 1,8 2,5 % 0,5 1,1 1,5 1,8 2,0 3,5 % 0,5 1,2 1,6 1,9 2,1 4,5 % 0,5 1,2 1,7 2,0 2,2 5,5 % 0,5 1,3 1,8 2,1 2,3 15 Valuation Gene therapy and animal vaccines Key assumptions behind the estimates – Gene therapy Key assumptions behind the estimates – Animal vaccines The potential market size for gene therapy is estimated to be 61 billion euros. The market is developing very fast and the growth rate is estimated to be 12%. The market share is expected to be relatively low due to the high competition and wide range of applications. Royalty rate of 7% reflects high interest in gene therapy applications. Probability of licensing is 70%. Commercialization date is expected to be 2019. The applied discount rate is 25%. The market size for animal vaccines is estimated to be 5,2 billion euros. The market is growing rapidly and the growth rate is estimated to be 8%. The market share is expected to be 6% due to wide range of applications in the market. Royalty rate applied is 6%. Probability of licensing is 80%. Commercialization date is expected to be 2019. The applied discount rate is 25%. Discounted royalty and market share – Gene therapy Discounted royalty and market share – Animal vaccines Sensitivity analysis – Gene therapy Sensitivity analysis – Animal vaccines 25,9 2017 2018 2019 2020 2022 21 % 48,0 42,0 36,5 31,6 23,3 23 % 41,5 35,8 30,7 26,1 18,7 25 % 36,1 30,7 25,9 21,7 15,1 27 % 31,6 26,5 22,0 18,2 12,3 29 % 27,8 22,9 18,8 15,3 10,0 Source: Company, FIM Top market share MEUR Year of commercialization MEUR 25,9 1% 3% 5% 7% 9% 2,5 2017 2018 2019 2020 2022 10,0 % 6,6 16,6 23,3 27,6 30,3 21 % 4,6 4,0 3,5 3,0 2,2 11,0 % 6,9 17,5 24,6 29,2 32,0 23 % 4,1 3,5 2,9 2,5 1,7 12,0 % 7,3 18,4 25,9 30,8 33,8 25 % 3,6 3,0 2,5 2,1 1,4 13,0 % 7,6 19,3 27,3 32,5 35,7 27 % 3,2 2,6 2,2 1,8 1,2 14,0 % 8,0 20,3 28,8 34,3 37,7 29 % 2,8 2,3 1,9 1,5 1,0 Initial market growth MEUR Discount rate Year of commercialization Initial market growth Discount rate MEUR Top market share 2,5 2% 4% 6% 8% 10 % 6,0 % 0,9 1,7 2,3 2,7 3,1 7,0 % 1,0 1,7 2,4 2,9 3,3 8,0 % 1,0 1,8 2,5 3,1 3,5 9,0 % 1,1 1,9 2,6 3,2 3,7 10,0 % 1,1 2,0 2,8 3,4 3,9 16 Valuation HPV Key assumptions behind the estimates – HPV The market size for HPV vaccines is estimated to be 1,7 billion euros. The market is relatively mature and the growth rate is estimated to be 1,5%. The market share is expected to 15%. Royalty rate is 6%- Probability of licensing is 70%. Commercialization date is expected to be 2023. The applied discount rate is 25%. Discounted royalty and market share – HPV Sensitivity analysis – HPV Year of commercialization MEUR 0,7 2021 2022 2023 2024 2026 21 % 1,5 1,2 1,0 0,9 0,6 23 % 1,2 1,0 0,8 0,7 0,5 25 % 1,0 0,8 0,7 0,6 0,4 27 % 0,9 0,7 0,6 0,4 0,3 29 % 0,7 0,6 0,5 0,4 0,2 Source: Company, FIM Initial market growth Discount rate MEUR Top market share 0,7 11 % 13 % 15 % 17 % 19 % 1,0 % 0,5 0,5 0,6 0,6 0,7 2,0 % 0,5 0,6 0,6 0,7 0,8 3,0 % 0,5 0,6 0,7 0,7 0,8 4,0 % 0,6 0,6 0,7 0,8 0,9 5,0 % 0,6 0,7 0,8 0,8 0,9 17 Disclaimer This report has been made by FIM Investment Services Ltd. The information in this report is based on publicly available data and information from various sources deemed reliable, but has not been independently verified by FIM Investment Services Ltd and/or its affiliate(s), (herein referred collectively to as FIM), which therefore does not guarantee that the information is comprehensive and accurate. All views expressed herein are those of the author(s) at the time of writing and may change without notice. FIM holds no obligation to update, modify or amend this publication or to otherwise notify a reader or recipient of this publication in the event that any matter, opinion, projection, forecast or estimate contained herein changes or subsequently becomes inaccurate. The research material produced by FIM is informative in nature, and should not be interpreted as a recommendation to take, or not to take, any particular investment action. This research does not represent an offer or an invitation to buy, sell or subscribe for shares in the company(-ies) under analysis. This report does not take into regard the specific investment objectives, financial situation or the knowledge or experience of any specific person who may receive this report. Before making an investment decision, recipients are urged to seek expert advice and get well acquainted with the investment market and different investment alternatives. Any loss arising from the use of the information or opinions expressed in this report shall be the sole and exclusive responsibility of the investor. FIM accepts no liability for any possible losses or other consequences arising from decisions based on information or opinions expressed in this report or on information acquired from the FIM websites. There are always financial risks related to investment activities, such as the risk of no yield or the risk of losing the capital invested. Past performance does not indicate nor guarantee future performance of an investment. Some investments discussed by FIM have high volatility and may therefore experience sudden and large changes in value that may cause losses. It should further be noted that international investing includes risks related to political and economic uncertainties as well as currency risk. FIM is organised with procedures to prevent and avoid any conflict of interest. This includes inter alia routines regarding the secure handling of insider information. In addition Chinese Wall procedures are in place between the research analysts and employees involved in securities trading for the account of FIM or clients to ensure that price sensitive information is handled according to applicable laws and regulations. FIM acts as a market maker or liquidity provider on following companies: Apetit, Atria, Cleantech Invest, Etteplan, Honkarakenne, Innofactor, Martela, Siili Solutions, Soprano ja Trainers’ House. Analysis has been prepared by FIM analysts Aaron Kaartinen and Kim Gorschelnik. FIT Biotech management has been presented the document prior to publishing. FIM has made an agreement with the company this study concerns according to which it receives compensation for the research service provided. FIM does not provide any investment recommendation for the share. The research reports and other information received from FIM are meant for private use only. The materials may not be copied, quoted or distributed, in part or in whole, without written permission from FIM. The author of this report may be compensated with a bonus based on his/her personal performance and the overall financial performance of FIM. This report is a brief summary and does not purport to contain all available information on the subjects covered. Regulators: FIM Investment Services Ltd: The Financial Supervisory Authority of Finland (www.finanssivalvonta.fi) UNITED STATES This report or copies of it must not be distributed in the United States or to recipients who are citizens of the United States against restrictions stated in the United States legislation. Distributing the report in the United States might be seen as a breach of these laws. CANADA The information provided in this publication is not intended to be distributed or circulated in any manner in Canada and therefore should not be construed as any kind of financial recommendation or advice provided within the meaning of Canadian securities laws. OTHER COUNTRIES Laws and regulations of other countries may also restrict the distribution of this report. For further information relating to research recommendations and conflict of interest management see: www.fim.com. 18 Contact Information Equities Research Hans Segercrantz, 09 4390 1422 Kim Gorschelnik, 09 6134 6422 Richard Johansson, 09 6134 6202 Mika Metsälä, 09 6134 6304 Kari Lappalainen, 09 4390 1425 Aaron Kaartinen, 09 6134 6430 Sami Listola, 09 6134 6234 Jussi Matinlompolo, 09 6134 6428 Antti Pajukka, 09 6134 6321 Thomas Pirker, 09 6134 6222 FIM Direct, Order routing Clearing, Settlement and Custody Services Teemu Riihijärvi, 09 6134 6206 Heli Sirkiä, 09 6134 6335 Janne Virtanen, 09 6134 6362 19